ACELRX PHARMACEUTICALS INC (ACRX)

US00444T2096 - Common Stock

0.86  +0.06 (+7.5%)

After market: 0.8719 +0.01 (+1.38%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ACELRX PHARMACEUTICALS INC

NASDAQ:ACRX (1/9/2024, 7:00:00 PM)

After market: 0.8719 +0.01 (+1.38%)

0.86

+0.06 (+7.5%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-28.93%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap14.58M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACRX Daily chart

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.

Company Info

ACELRX PHARMACEUTICALS INC

1850 Gateway Drive, Suite 175

San Mateo CALIFORNIA 94063

P: 16502163500

CEO: Vincent J. Angotti

Employees: 19

Website: https://www.acelrx.com

ACRX News

News Image6 months ago - Seeking AlphaAcelRx announces rebranding with name change to Talphera (NASDAQ:ACRX)

AcelRx Pharmaceuticals announces rebranding and name change to Talphera; stock to commence trading as TLPH on Nasdaq starting January 10, 2024.

News Image6 months ago - Talphera, Inc.AcelRx Announces Rebranding With Name Change to Talphera, Inc.

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

News Image7 months ago - Seeking AlphaAcelRx Pharmaceuticals says CEO Angotti buys 10K shares in co (NASDAQ:ACRX)

AcelRx Pharmaceuticals CEO purchases 10K shares, increasing total holdings to 101.8K. Recent insider trading activity shows 7 buys and 0 sales.

News Image7 months ago - AcelRx Pharmaceuticals, Inc.AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...

News Image7 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

News Image8 months ago - Seeking AlphaAcelRx Pharmaceuticals files for $150M mixed shelf (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M.This prospectus is not an offer to...

ACRX Twits

Here you can normally see the latest stock twits on ACRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example